Xiangya Hospital, Central South University, Changsha, China.
The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston.
Arthritis Care Res (Hoboken). 2023 May;75(5):956-966. doi: 10.1002/acr.25028. Epub 2022 Nov 17.
To determine whether patients with rheumatoid arthritis (RA) are at higher risks for SARS-CoV-2 infection and its severe outcomes before and after COVID-19 vaccination.
Using a UK primary care database, we conducted 2 cohort studies to compare the risks of SARS-CoV-2 infection, hospitalization, and death from COVID-19 between patients with RA and the general population according to their COVID-19 vaccination status. We used exposure score overlap weighting to balance baseline characteristics between 2 comparison cohorts.
Among unvaccinated individuals, the weighted incidence rates of SARS-CoV-2 infection (9.21 versus 8.16 of 1,000 person-months), hospitalization (3.46 versus 2.14 of 1,000 person-months), and death (1.19 versus 0.62 of 1,000 person-months) were higher among patients with RA than the general population over 3 months of follow-up; the corresponding adjusted hazard ratios (HRs) were 1.10 (95% confidence interval [95% CI] 1.00-1.24), 1.62 (95% CI 1.34-1.96), and 1.88 (95% CI 1.37-2.60), respectively. Among vaccinated individuals, the weighted rates of breakthrough infection (4.17 versus 3.96 of 1,000 person-months; HR 1.10 [95% CI 1.00-1.20]) and hospitalization (0.42 versus 0.32 of 1,000 person-months; HR 1.29 [95% CI 0.96-1.75]) were higher among patients with RA than the general population over 9 months of follow-up; however, no apparent difference in the risk of these outcomes was observed over 3 and 6 months of follow-up between 2 comparison cohorts.
Patients with RA are still at higher risks of SARS-CoV-2 infection and COVID-19 hospitalization than the general population after receiving COVID-19 vaccines. These findings support booster COVID-19 vaccinations and adherence of other preventive strategies among patients with RA.
确定类风湿关节炎(RA)患者在 COVID-19 疫苗接种前后感染 SARS-CoV-2 及其严重后果的风险是否更高。
我们使用英国初级保健数据库进行了两项队列研究,根据 COVID-19 疫苗接种情况,比较了 RA 患者和普通人群 SARS-CoV-2 感染、住院和 COVID-19 死亡的风险。我们使用暴露评分重叠加权来平衡两个比较队列之间的基线特征。
在未接种人群中,RA 患者在 3 个月的随访中 SARS-CoV-2 感染(9.21 与 8.16/1000 人月)、住院(3.46 与 2.14/1000 人月)和死亡(1.19 与 0.62/1000 人月)的加权发生率均高于普通人群;相应的调整后的危险比(HR)分别为 1.10(95%置信区间 [95%CI] 1.00-1.24)、1.62(95%CI 1.34-1.96)和 1.88(95%CI 1.37-2.60)。在接种人群中,RA 患者在 9 个月的随访中突破性感染(4.17 与 3.96/1000 人月;HR 1.10 [95%CI 1.00-1.20])和住院(0.42 与 0.32/1000 人月;HR 1.29 [95%CI 0.96-1.75])的加权率均高于普通人群;然而,在 3 个月和 6 个月的随访中,两个比较队列之间并未观察到这些结局风险的明显差异。
RA 患者在接种 COVID-19 疫苗后,仍面临更高的 SARS-CoV-2 感染和 COVID-19 住院风险。这些发现支持 RA 患者加强 COVID-19 疫苗接种和采取其他预防策略。